Prevention of relapse in reflux esophagitis: a placebo controlled study of ranitidine 150 mg bid and 300 mg bid.

Hegarty, J H; Halvorsen, L; Hazenberg, B P; Nowak, A; Smith, C L; Thomson, A B; Vantrappen, G; McKenna, C J; Mills, J G

Hegarty, J H; Halvorsen, L; Hazenberg, B P; Nowak, A; Smith, C L; Thomson, A B; Vantrappen, G; McKenna, C J; Mills, J G.

Affiliation

Hegarty JH; St. Vincent's Hospital, Dublin, Eire.

Can J Gastroenterol ; 11(1): 83-8, 1997.

Article in En | MEDLINE | ID: mdl-9113805

Subject(s)

Esophagitis, Peptic/drug therapy; Esophagitis, Peptic/prevention & control; Histamine H2 Antagonists/administration & dosage; Ranitidine/administration & dosage; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Esophagitis, Peptic/physiopathology; Esophagoscopy; Female; Humans; Logistic Models; Male; Middle Aged; Recurrence; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Ranitidine / Esophagitis, Peptic / Histamine H2 Antagonists Type of study: Clinical_trials / Risk_factors_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Can J Gastroenterol Journal subject: GASTROENTEROLOGIA Year: 1997 Document type: Article Country of publication: Canada

Search on Google

Add to My VHL

XML

PubMed Links